NXTM - NxStage Medical, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
30.00
+0.01 (+0.03%)
As of 4:00PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close 29.99
Open 30.00
Bid 0.00 x 305200
Ask 0.00 x 800
Day's Range 29.98 - 30.00
52 Week Range 25.53 - 30.00
Volume 2,608,346
Avg. Volume 1,470,084
Market Cap 2.001B
Beta (3Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) N/A
Earnings Date Nov 1, 2017 - Nov 6, 2017
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 30.00
Trade prices are not sourced from all markets
  • Reuters 2 months ago

    FMC wraps up $2 bln acquisition of NxStage

    Germany's Fresenius Medical Care (FMC) wrapped up its $2 billion acquisition of U.S. home dialysis maker NxStage Medical on Friday, according to a U.S. Securities and Exchange Commission filing. The closure - some 18 months after FMC agreed to buy NxStage - paves the way for the world's biggest provider of dialysis services to scale up its home dialysis business by investing in new infrastructure, patient training and education.

  • Reuters 2 months ago

    Deals of the day-Mergers and acquisitions

    (Adds Ophir Energy, Alitalia, Bristol-Myers Squibb, Cemex, Tilray, Magellan Health, Verus Petroleum, Owens & Minor; Updates Bank Audi, Sainsbury) Feb 20 (Reuters) - The following bids, mergers, acquisitions ...

  • Fresenius Medical Care AG & Co. (FMS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool 2 months ago

    Fresenius Medical Care AG & Co. (FMS) Q4 2018 Earnings Conference Call Transcript

    FMS earnings call for the period ending December 31, 2018.

  • FMC expects NxStage deal to close in next couple of days
    Reuters 2 months ago

    FMC expects NxStage deal to close in next couple of days

    Germany's Fresenius Medical Care (FMC) said on Wednesday it has won the green light from U.S. regulators to acquire U.S. home dialysis equipment maker NxStage and expects the deal to close in the next few days. FMC agreed to buy NxStage in August 2017 for $2 billion but the deal has been held up due to competition concerns and most recently the U.S. government shutdown. "Very early this morning, we were notified the Federal Trade Commission has approved our NxStage deal," Chief Executive Rice Powell told reporters.

  • Reuters 2 months ago

    U.S. approves Fresenius purchase of NxStage

    The U.S. Federal Trade Commission has given Germany's Fresenius Medical Care AG and U.S. home dialysis equipment maker NxStage Medical Inc antitrust approval for their merger, the agency said on Tuesday. To win approval for the $2 billion deal, the companies agreed to sell NxStage's bloodline tubing set business, the agency said. Fresenius and NxStage together dominate the market for the single-use plastic tubes used during dialysis, the agency said.

  • Markit 2 months ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTMView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for NXTM with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting NXTM. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding NXTM totaled $1.90 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 4 Healthcare Stocks Likely to Beat Estimates in Q4
    Zacks 3 months ago

    4 Healthcare Stocks Likely to Beat Estimates in Q4

    An aging population, prevalence of chronic health conditions and greater utilization of healthcare services should drive the industry's growth, partly offset by an increase in expenses.

  • Reuters 3 months ago

    FMC extends deadline for NxStage deal until Aug. 6 due to U.S. government shutdown

    Germany's Fresenius Medical Care (FMC) said on Tuesday it had agreed to extend the deadline for its planned $2 billion takeover of U.S. home dialysis equipment maker NxStage Medical Inc until August 6. FMC said the extension had been agreed due to the recent U.S. government shutdown which interrupted the Federal Trade Commission's (FTC) ability to review the transaction.

  • GlobeNewswire 3 months ago

    Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • 4 Medical Product Stocks Likely to Top Q4 Earnings Estimates
    Zacks 3 months ago

    4 Medical Product Stocks Likely to Top Q4 Earnings Estimates

    Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.

  • Is NxStage Medical, Inc. (NXTM) A Good Stock To Buy?
    Insider Monkey 4 months ago

    Is NxStage Medical, Inc. (NXTM) A Good Stock To Buy?

    After several tireless days we have finished crunching the numbers from the more than 700 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30. The results of that effort will be put on display in this […]

  • GlobeNewswire 5 months ago

    Investor Expectations to Drive Momentum within NxStage Medical, Hertz Global, Kohl's, Valvoline, Yelp, and TransMontaigne Partners — Discovering Underlying Factors of Influence

    NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • NxStage Medical (NXTM) Beats Q3 Earnings and Revenue Estimates
    Zacks 5 months ago

    NxStage Medical (NXTM) Beats Q3 Earnings and Revenue Estimates

    NxStage (NXTM) delivered earnings and revenue surprises of 150.00% and 0.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • NxStage Is Back to Making Money
    Motley Fool 5 months ago

    NxStage Is Back to Making Money

    Patient investors are still waiting for news on the dialysis specialist's expected merger.

  • Will NxStage Medical (NXTM) Report Negative Earnings Next Week? What You Should Know
    Zacks 6 months ago

    Will NxStage Medical (NXTM) Report Negative Earnings Next Week? What You Should Know

    NxStage (NXTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • NxStage Announces Significant Increase in Nx2me Connected Health® Platform Adoption
    PR Newswire 6 months ago

    NxStage Announces Significant Increase in Nx2me Connected Health® Platform Adoption

    "We are really beginning to see a shift toward using innovative telehealth solutions to help improve patient outcomes with home dialysis," said Dr.  Michael Kraus, Associate Chief Medical Officer for NxStage. "Nx2me is an intuitive tool to support and proactively engage with home hemodialysis patients. A key component of the Nx2me platform is the Nx2me iPad® app, which is designed to increase patients' ease of use of home therapy by capturing treatment data and wirelessly sending it to their center after each treatment, thereby reducing the need for paper flow sheets.